Showing results (1-10 of 2,039) with videos related to
Sort By:
Pageof 204
Cancer Chemotherapy and Pharmacology|February 18, 2010
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?N A Helsby, W Y Lo, P Thompson, et al.Cancer Chemotherapy and Pharmacology|November 29, 2015
High CYP2C19 phenotypic variability in gastrointestinal cancer patientsK E Burns, W-Y Lo, M P Findlay, et al.British Journal of Cancer|October 16, 2008
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeN A Helsby, W-Y Lo, K Sharples, et al.The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|April 26, 2003
On the development of rational standards for nuclear response evaluationG R Laking, P M PriceThe British Journal of Radiology|October 1, 2004
Positron emission tomographic imaging of angiogenesis and vascular functionG R Laking, P M PriceEnvironmental Toxicology and Pharmacology|July 26, 2011
Can in vitro drug metabolism studies with human tissue replace in vivo animal studies?M D Tingle, N A HelsbyEuropean Journal of Cancer (Oxford, England : 1990)|October 22, 2002
Assessment of the technology for functional imaging in cancerG R Laking, P M Price, M J SculpherBritish Journal of Clinical Pharmacology|April 1, 1995
The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanidesJ D Wright, N A Helsby, S A WardFood and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|July 14, 1998
Inhibition of mouse and human CYP 1A- and 2E1-dependent substrate metabolism by the isoflavonoids genistein and equolN A Helsby, J K Chipman, A Gescher, et al.British Journal of Clinical Pharmacology|June 1, 1993
The multiple dose pharmacokinetics of proguanilN A Helsby, G Edwards, A M Breckenridge, et al.Pageof 204